{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"myelodysplastic-syndrome-with-excess-blasts-2","columns":[],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":[],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":[],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":0,"emptyColumnKeys":[],"hpoRelease":"not available","narrativeSourceChanges":[],"records":0,"sourceGroups":{}},"features":[],"ledeHtml":"A myelodysplastic syndrome defined by 10-19% blasts in the bone marrow or 5-19% blasts in the blood and &lt;10% blasts in the bone marrow. Approximately 33% of cases progress to acute leukemia. The prognosis is usually poor. (WHO)","mondoId":"MONDO:0015041","node":{"canonicalSlug":"myelodysplastic-syndrome-with-excess-blasts-2","comparisons":[],"contexts":[],"lifecycle":"active","narrative":{"causes":[],"contentForm":"definition-only","matchMethod":"same-ontology-node","name":"myelodysplastic syndrome with excess blasts-2","paragraphs":["A myelodysplastic syndrome defined by 10-19% blasts in the bone marrow or 5-19% blasts in the blood and <10% blasts in the bone marrow. Approximately 33% of cases progress to acute leukemia. The prognosis is usually poor. (WHO)"],"scope":"exact","source":"MONDO","upstream":"NCIT:C7168","url":"https://monarchinitiative.org/MONDO:0015041"},"ownColumnKeys":[],"publication":"published","relationships":[{"kind":"parent","label":"myelodysplastic syndrome with excess blasts","mondoId":"MONDO:0019454","slug":"myelodysplastic-syndrome-with-excess-blasts"}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[{"reason":"Public source record is not available in the frozen inputs","source":"GARD","url":"https://rarediseases.info.nih.gov/diseases/19738"}],"translation":"published"},"records":[],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0015041\" rel=\"noreferrer\">MONDO</a></p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>definition-only</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>same-ontology-node</dd><dt>Upstream attribution</dt><dd>NCIT:C7168</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>A myelodysplastic syndrome defined by 10-19% blasts in the bone marrow or 5-19% blasts in the blood and &lt;10% blasts in the bone marrow. Approximately 33% of cases progress to acute leukemia. The prognosis is usually poor. (WHO)</p><p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0015041\" rel=\"noreferrer\">MONDO</a></p>","key":"overview","title":"Brief description"}],"sharedSources":[],"slug":"myelodysplastic-syndrome-with-excess-blasts-2","sourceDocuments":[{"name":"MONDO: myelodysplastic syndrome with excess blasts-2","reviewed":null,"source_release":"releases/2026-10-06","url":"https://monarchinitiative.org/MONDO:0015041"}],"sourceNote":"","synonyms":["MDS-EB-2","myelodysplastic syndrome with Excess blasts-2","RAEB-2","RAEB-II","refractory anaemia with excess blasts type 2"],"takeawayHtml":"","title":"myelodysplastic syndrome with excess blasts-2"},"schemaVersion":1}
